|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zachary Rome, Jessica Raiz, MPH, and Alan M. Mendelsohn, MD, are advancing innovative clinical research that is evaluating high-potential, low-risk treatments for rare dermatologic diseases using unique topical vehicles combined with established medications that enable the targeted delivery of therapies to the epidermis and dermis while minimizing systemic absorption.
|
|
|
David Lowe, PhD, Justin Hean, PhD, Dave Carter, PhD, and Antonin de Fougerolles, PhD, say EVs exhibit key properties that make them extremely attractive as therapeutics, particularly their safety profile and potential for low immunogenicity. In order to effectively unlock this potential, some key challenges remain, such as the development of EV product manufacture and characterization methodologies and rapid pharmacokinetics.
|
|
|
Jeremy R. Graff, PhD, says new studies show promising data with the use of mRNA-based vaccines and the injection of nanoparticles into regional lymph nodes to achieve disease stabilization. This has led to a potentially groundbreaking era of therapeutic cancer vaccines thanks to discoveries in identifying truncal targets, targeting tumor neoantigens and, notably, developing improved delivery technologies that stimulate a robust, targeted, and persistent immune response.
|
|
|
Jeffrey Tillack, Chief Operating Officer at Credence MedSystems, discusses the challenges being addressed by his innovative technology and the role its new Flex Line will play in the company’s scaling strategy.
|
|
|
Get ready to elevate your aseptic manufacturing game with this complete guide! All the info you need is within this must-have e-Book.
|
|
|
|
|
|
|
|
|

Micropore Technologies is a global process technology and service provider to the pharmaceutical industry featuring patented crossflow technology for the commercially scalable development of topical and sterile injectable drug products. Originally spun-out of Loughborough University’s internationally renowned chemical engineering department, the company’s global headquarters and technical center are located at Wilton Center, UK with offices and operations in the USA, India, South Korea & Japan supporting over a hundred clients and strategic partners. Micropore’s technology enables scalable formulation of mono-disperse microspheres, nanoparticles and emulsions. Our array of mixing devices are constructed to operate from early stage high throughput screening on the benchtop to fully integrated GMP manufacturing SKIDs. We offer best in class formulation consultation, in house discovery through preclinical feasibility trials, and process engineering services to supporting the development of commercial manufacturing processes. Click here for more.
|
|
|
|
|
|
 |
|
Rallybio Corporation and EyePoint Pharmaceuticals, Inc recently announced a research collaboration. The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component….
|
|
 |
|
Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer….
|
|
 |
|
Ocean Biomedical, Inc. celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant….
|
|
 |
|
Cue Biopharma, Inc. recently announced a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. for CUE-401, a bispecific protein designed to induce and expand regulatory….
|
|
 |
|
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced the development of a new enzyme for double strand oligonucleotide formation with high….
|
|
|
|
|
|
|
|
 |
|
Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …
|
|
 |
|
Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.
The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …
|
|
 |
|
Manufacturing Phase 1 clinical material in as little as 12–16 months
Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …
|
|
 |
|
Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …
|
|
 |
|
Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.
Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …
|
|
 |
|
Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.
Download our whitepaper and learn …
|
|
|
|
|
Upcoming eNewsletter Features:
March 8 – Parenteral Contract Manufacturing
March 15 – Polymers & Biomaterials
|
|
|
|
|
|
|
|